The abstract is read at the publisher; the summary is JClub's.
Universal infant nirsevimab prophylaxis in the NIRSE-GAL study is linked to a sustained 55·3% reduction in RSV-related LRTI hospitalisations in the second season.
- Why it matters: The second-season persistence matters because nirsevimab does not give sterilising immunity, so durable protection needs mechanistic explanation and careful interpretation.
- What they did: The NIRSE-GAL evaluation compared RSV-related lower respiratory tract infection hospitalisations across seasons after prophylaxis, reporting a second-season reduction with 95% CI 22·5–74·3.
- The result: The findings show no evidence of enhanced disease or an age-related severity shift, supporting cautious, testable hypotheses for how lung-sparing, endotype selection, and antigen exposure could sustain benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.